Research Analysts Offer Predictions for Sanofi Q3 Earnings

Sanofi (NASDAQ:SNY) – Stock analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for shares of Sanofi in a report issued on Monday, January 27th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings of $1.57 per share for the quarter. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Leerink Partnrs also issued estimates for Sanofi’s Q4 2025 earnings at $0.91 EPS and FY2029 earnings at $5.88 EPS.

Separately, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Sanofi Trading Down 1.1 %

NASDAQ:SNY opened at $52.37 on Wednesday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The stock’s 50 day moving average price is $48.99 and its 200 day moving average price is $52.22. The company has a market capitalization of $132.92 billion, a PE ratio of 26.72, a P/E/G ratio of 1.19 and a beta of 0.57.

Institutional Trading of Sanofi

A number of hedge funds have recently added to or reduced their stakes in SNY. McClarren Financial Advisors Inc. lifted its stake in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the period. Van ECK Associates Corp raised its holdings in Sanofi by 18.1% during the fourth quarter. Van ECK Associates Corp now owns 662,762 shares of the company’s stock worth $31,965,000 after purchasing an additional 101,726 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Sanofi by 128.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 115,330 shares of the company’s stock valued at $5,558,000 after purchasing an additional 64,747 shares during the period. Kentucky Trust Co purchased a new stake in Sanofi in the 4th quarter valued at approximately $436,000. Finally, Certuity LLC increased its position in Sanofi by 20.3% during the 4th quarter. Certuity LLC now owns 4,592 shares of the company’s stock worth $221,000 after purchasing an additional 776 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.